Ibudilast + Placebo oral capsule
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alcohol Use Disorder
Conditions
Alcohol Use Disorder
Trial Timeline
Oct 1, 2018 → Apr 19, 2023
NCT ID
NCT03594435About Ibudilast + Placebo oral capsule
Ibudilast + Placebo oral capsule is a phase 2 stage product being developed by MediciNova for Alcohol Use Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03594435. Target conditions include Alcohol Use Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03594435 | Phase 2 | Completed |
| NCT01982942 | Phase 2 | Completed |
Competing Products
20 competing products in Alcohol Use Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 47 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 30 |
| IVA337 + IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| Lanifibranor | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo + Empagliflozin | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo | Inventiva | Phase 3 | 72 |
| LY686017 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3537031 + Placebo | Eli Lilly | Phase 3 | 77 |
| AD04 (ondansetron) + Matching placebo | Adial Pharmaceuticals | Phase 3 | 69 |
| GODEX + Placebo | Celltrion | Phase 3 | 77 |
| Colesevelam Hcl | Daiichi Sankyo | Phase 2 | 52 |
| ASP9831 + Placebo | Astellas Pharma | Phase 2 | 52 |
| ASP8062 + Placebo | Astellas Pharma | Phase 2 | 52 |
| LY686017 + Placebo | Eli Lilly | Phase 2 | 52 |
| Mazdutide + Placebo | Eli Lilly | Phase 2 | 52 |
| opioid receptor kappa antagonist | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2196044 + placebo | Eli Lilly | Phase 2 | 52 |